Vinorelbine and Ifosfamide as Third-line Treatment for Refractory Small Cell Lung Cancer
NCT01752517
·
clinicaltrials.gov ↗
UNKNOWN
Status
60
Enrollment
OTHER
Sponsor class
Conditions
Small Cell Lung Cancer
Interventions
DRUG:
NI group
Sponsor
Peking Union Medical College Hospital